Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia
暂无分享,去创建一个
R. Kozlov | E. Kolesnikova | I. Edelstein | N. Rudneva | I. V. Trushin | A. Kuzmenkov | I. V. Borisov | A. V. Romanov | L. M. Zubareva | L. Sukhanova | A.M. Akhmedova | O.P. Novikova | A. Romanov
[1] K. Workowski,et al. Sexually Transmitted Infections Treatment Guidelines, 2021 , 2021, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[2] K. Muldrew,et al. Retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern USA , 2021, BMJ Open.
[3] E. Shedko,et al. Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region , 2021, European Journal of Clinical Microbiology & Infectious Diseases.
[4] N. Low,et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. , 2020, The Lancet. Infectious diseases.
[5] M. Unemo,et al. Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis , 2020, Journal of Clinical Microbiology.
[6] C. Cartwright,et al. Prevalence of Mycoplasma genitalium infection in women with bacterial vaginosis , 2020, BMC Women's Health.
[7] N. Luhmann,et al. HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors , 2020, Sexually Transmitted Infections.
[8] M. Unemo,et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[9] T. Pumarola,et al. Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review , 2020, International journal of STD & AIDS.
[10] J. G. Kusters,et al. Molecular Basis of Antibiotic Resistance in Mycoplasma genitalium. , 2020, International journal of antimicrobial agents.
[11] O. Zhukova,et al. The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018 , 2020 .
[12] S. Pereyre,et al. Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium , 2019, Journal of Clinical Microbiology.
[13] S. Soni,et al. High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic , 2019, BMJ Sexual & Reproductive Health.
[14] B. Elmoualij,et al. Four-color multiplex real-time PCR assay prototype targeting azithromycin resistance mutations in Mycoplasma genitalium , 2019, BMC Infectious Diseases.
[15] T. Pumarola,et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study , 2019, Sexually Transmitted Infections.
[16] S. Garland,et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] I. Edelstein,et al. The rates of mutations associated with macrolide resistance in Mycoplasma genitalium among patients with non-gonococcal sexually transmitted infections in Smolensk and Tula , 2019, Clinical Microbiology and Antimicrobial Chemotherapy.
[18] M. Edelstein,et al. AMRcloud: a new paradigm in monitoring of antibiotic resistance , 2019, Clinical Microbiology and Antimicrobial Chemotherapy.
[19] H. Fifer,et al. Mycoplasma genitalium: A Review. , 2019, Microbiology.
[20] А. В. Романов,et al. Клинический случай неуспеха терапии джозамицином у пациента с уретритом, вызванным Mycoplasma genitalium , 2018 .
[21] J. Ong,et al. Mycoplasma genitalium: an important sexually transmitted infection comes into focus , 2018, Sexually Transmitted Infections.
[22] M. Unemo,et al. Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties, 2011–2015 , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[23] J. G. Kusters,et al. Mycoplasma genitalium in Spain: prevalence of genital infection and frequency of resistance to macrolides. , 2017, Enfermedades infecciosas y microbiologia clinica.
[24] A. Bahador,et al. Improvement of semen parameters after antibiotic therapy in asymptomatic infertile men infected with Mycoplasma genitalium , 2018, Infection.
[25] S. Sethi,et al. Mycoplasma genitalium infections: current treatment options and resistance issues , 2017, Infection and drug resistance.
[26] H. Wiesenfeld,et al. Mycoplasma genitalium in Women: Current Knowledge and Research Priorities for This Recently Emerged Pathogen , 2017, The Journal of infectious diseases.
[27] S. Philip,et al. P2.05 A silent epidemic: the prevalence, incidence and persistence of mycoplasma genitalium in young asymptomatic women in the united states , 2017, Sexually Transmitted Infections.
[28] M. Unemo,et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia , 2017, PloS one.
[29] S. Garland,et al. Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of Mycoplasma genitalium and Macrolide Resistance , 2017, Journal of Clinical Microbiology.
[30] S. Garland,et al. Azithromycin 1.5g Over 5 Days Compared to 1g Single Dose in Urethral Mycoplasma genitalium: Impact on Treatment Outcome and Resistance , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] S. Resch,et al. Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016-2021 , 2017, PloS one.
[32] S. Pereyre,et al. Evaluation of a Commercial Multiplex Quantitative PCR (qPCR) Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance-Associated Mutations in Clinical Specimens , 2016, Journal of Clinical Microbiology.
[33] M. Cusini,et al. 2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.
[34] W. I. van der Meijden,et al. 2016 European guideline on the management of non-gonococcal urethritis , 2016, International journal of STD & AIDS.
[35] N. Anisimova,et al. The Aexperience of the Organization and the Screening of Pregnant Women for the Purpose of Detecting Sexually Transmitted Infections, in the Framework of the Regional Program of the Tula Region , 2015 .
[36] David Bruce Lewis,et al. Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations , 2015, Infection and drug resistance.
[37] E. Smit,et al. Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic , 2015, International journal of STD & AIDS.
[38] M. Unemo,et al. Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin , 2015, BMC Infectious Diseases.
[39] P. Azzopardi,et al. Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne , 2014, International journal of STD & AIDS.
[40] M. Unemo,et al. Guidelines for the laboratory diagnosis of mycoplasma genitalium infections in East European countries. , 2010, Acta dermato-venereologica.
[41] J. Jensen,et al. Tetracycline treatment does not eradicate Mycoplasma genitalium , 2003, Sexually transmitted infections.
[42] S. Pereyre,et al. Mutations in 23S rRNA Account for Intrinsic Resistance to Macrolides in Mycoplasma hominis and Mycoplasma fermentans and for Acquired Resistance to Macrolides in M. hominis , 2002, Antimicrobial Agents and Chemotherapy.